Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Rosuvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) has been shown to be excreted mostly unchanged into the bile; interactions on the level of hepatic apical efflux transporters may represent a risk of liver toxicity. So far, controversial and insufficient data are available concerning transporters involved in the elimination process. This study was designed to elucidate, which transporters take part in the biliary clearance of rosuvastatin using sandwich-cultured primary rat hepatocytes. The canalicular efflux of rosuvastatin was measured in the presence of inhibitors: Ko 134, mitoxanthrone, novobiocin for breast cancer resistance protein (Bcrp); verapamil for multidrug resistance protein (Mdr1); benzbromarone, sulfasalazine, probenecid for multidrug resistance associated protein (Mrp 2); and cyclosporine A, glibenclamide, troglitazone for bile salt export pump (Bsep). Mrp2 inhibitors decreased the biliary efflux of rosuvastatin most potently by 78.9%, 35%, 54.1%; benzbromarone, probenecid, sulfasalazine, respectively, while Bcrp and Bsep inhibitors showed much less effect (29.1%, 23.0%,30.0%; Ko 134, mitoxanthrone, novobiocin, respectively, and 32.6%, 29.3%, 20.6%, glibenclamide, cyclosporine A, troglitazone, respectively). The marked decline of canalicular transport by Mrp2 inhibitors suggests major role of Mrp2 in this process; however, Bcrp and Bsep might also contribute to the biliary elimination of rosuvatatin in sandwich-cultured rat hepatocytes.

Original languageEnglish
Pages (from-to)605-610
Number of pages6
JournalToxicology in Vitro
Volume24
Issue number2
DOIs
Publication statusPublished - Mar 2010

Fingerprint

troglitazone
Rats
Hepatocytes
Benzbromarone
Bile Acids and Salts
Novobiocin
Probenecid
Sulfasalazine
Glyburide
Pumps
Breast Neoplasms
Cyclosporine
P-Glycoproteins
Multidrug Resistance-Associated Proteins
Proteins
Liver
Verapamil
Bile
Toxicity
Oxidoreductases

Keywords

  • Biliary clearance
  • Hepatocytes
  • Rosuvastatin
  • Sandwich culture

ASJC Scopus subject areas

  • Toxicology

Cite this

@article{7acc211aa1084d06af2a788367cb6151,
title = "Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes",
abstract = "Rosuvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) has been shown to be excreted mostly unchanged into the bile; interactions on the level of hepatic apical efflux transporters may represent a risk of liver toxicity. So far, controversial and insufficient data are available concerning transporters involved in the elimination process. This study was designed to elucidate, which transporters take part in the biliary clearance of rosuvastatin using sandwich-cultured primary rat hepatocytes. The canalicular efflux of rosuvastatin was measured in the presence of inhibitors: Ko 134, mitoxanthrone, novobiocin for breast cancer resistance protein (Bcrp); verapamil for multidrug resistance protein (Mdr1); benzbromarone, sulfasalazine, probenecid for multidrug resistance associated protein (Mrp 2); and cyclosporine A, glibenclamide, troglitazone for bile salt export pump (Bsep). Mrp2 inhibitors decreased the biliary efflux of rosuvastatin most potently by 78.9{\%}, 35{\%}, 54.1{\%}; benzbromarone, probenecid, sulfasalazine, respectively, while Bcrp and Bsep inhibitors showed much less effect (29.1{\%}, 23.0{\%},30.0{\%}; Ko 134, mitoxanthrone, novobiocin, respectively, and 32.6{\%}, 29.3{\%}, 20.6{\%}, glibenclamide, cyclosporine A, troglitazone, respectively). The marked decline of canalicular transport by Mrp2 inhibitors suggests major role of Mrp2 in this process; however, Bcrp and Bsep might also contribute to the biliary elimination of rosuvatatin in sandwich-cultured rat hepatocytes.",
keywords = "Biliary clearance, Hepatocytes, Rosuvastatin, Sandwich culture",
author = "K. Jemnitz and Z. Veres and Regina Tugyi and L. Vereczkey",
year = "2010",
month = "3",
doi = "10.1016/j.tiv.2009.10.009",
language = "English",
volume = "24",
pages = "605--610",
journal = "Toxicology in Vitro",
issn = "0887-2333",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes

AU - Jemnitz, K.

AU - Veres, Z.

AU - Tugyi, Regina

AU - Vereczkey, L.

PY - 2010/3

Y1 - 2010/3

N2 - Rosuvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) has been shown to be excreted mostly unchanged into the bile; interactions on the level of hepatic apical efflux transporters may represent a risk of liver toxicity. So far, controversial and insufficient data are available concerning transporters involved in the elimination process. This study was designed to elucidate, which transporters take part in the biliary clearance of rosuvastatin using sandwich-cultured primary rat hepatocytes. The canalicular efflux of rosuvastatin was measured in the presence of inhibitors: Ko 134, mitoxanthrone, novobiocin for breast cancer resistance protein (Bcrp); verapamil for multidrug resistance protein (Mdr1); benzbromarone, sulfasalazine, probenecid for multidrug resistance associated protein (Mrp 2); and cyclosporine A, glibenclamide, troglitazone for bile salt export pump (Bsep). Mrp2 inhibitors decreased the biliary efflux of rosuvastatin most potently by 78.9%, 35%, 54.1%; benzbromarone, probenecid, sulfasalazine, respectively, while Bcrp and Bsep inhibitors showed much less effect (29.1%, 23.0%,30.0%; Ko 134, mitoxanthrone, novobiocin, respectively, and 32.6%, 29.3%, 20.6%, glibenclamide, cyclosporine A, troglitazone, respectively). The marked decline of canalicular transport by Mrp2 inhibitors suggests major role of Mrp2 in this process; however, Bcrp and Bsep might also contribute to the biliary elimination of rosuvatatin in sandwich-cultured rat hepatocytes.

AB - Rosuvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) has been shown to be excreted mostly unchanged into the bile; interactions on the level of hepatic apical efflux transporters may represent a risk of liver toxicity. So far, controversial and insufficient data are available concerning transporters involved in the elimination process. This study was designed to elucidate, which transporters take part in the biliary clearance of rosuvastatin using sandwich-cultured primary rat hepatocytes. The canalicular efflux of rosuvastatin was measured in the presence of inhibitors: Ko 134, mitoxanthrone, novobiocin for breast cancer resistance protein (Bcrp); verapamil for multidrug resistance protein (Mdr1); benzbromarone, sulfasalazine, probenecid for multidrug resistance associated protein (Mrp 2); and cyclosporine A, glibenclamide, troglitazone for bile salt export pump (Bsep). Mrp2 inhibitors decreased the biliary efflux of rosuvastatin most potently by 78.9%, 35%, 54.1%; benzbromarone, probenecid, sulfasalazine, respectively, while Bcrp and Bsep inhibitors showed much less effect (29.1%, 23.0%,30.0%; Ko 134, mitoxanthrone, novobiocin, respectively, and 32.6%, 29.3%, 20.6%, glibenclamide, cyclosporine A, troglitazone, respectively). The marked decline of canalicular transport by Mrp2 inhibitors suggests major role of Mrp2 in this process; however, Bcrp and Bsep might also contribute to the biliary elimination of rosuvatatin in sandwich-cultured rat hepatocytes.

KW - Biliary clearance

KW - Hepatocytes

KW - Rosuvastatin

KW - Sandwich culture

UR - http://www.scopus.com/inward/record.url?scp=76549126776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549126776&partnerID=8YFLogxK

U2 - 10.1016/j.tiv.2009.10.009

DO - 10.1016/j.tiv.2009.10.009

M3 - Article

C2 - 19853032

AN - SCOPUS:76549126776

VL - 24

SP - 605

EP - 610

JO - Toxicology in Vitro

JF - Toxicology in Vitro

SN - 0887-2333

IS - 2

ER -